Amniocentesis in pregnant HIV-infected patients. Absence of mother-to-child viral transmission in a series of selected patients

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 140, Issue 2, 2008, Pages 212-217

  Ekoukou, Dieudonné ^a   Khuong Josses, Marie Aude ^a   Ghibaudo, Nelly ^a   Mechali, Denis ^a   Rotten, Daniel ^a  

^a DELAFONTAINE HOSPITAL   (France)

Author keywords

Genetic amniocentesis; HIV vertical transmission; HIV infected pregnant women

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ADULT; AMNIOCENTESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELIVERY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTRAUTERINE INFECTION; LIVE BIRTH; MONOTHERAPY; PREGNANCY; PRIORITY JOURNAL; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 52949110962     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2008.04.004     Document Type: Article

References (23)

1. Giorlandino C., Gambuzza G., D'Alessio P., Santoro M.L., Gentili P., and Vizzone A. Blood contamination of amniotic fluid after amniocentesis in relation to placental location. Prenat Diag 16 (1996) 180-182
2. Delfraissy JF (under the direction of). Therapeutic management of human immunodeficiency virus-infected subjects (recommendations of the group of experts), Report to the Minister of Health, 2002 [http://www.sante.gouv.fr/htm/actu/delfraissy/].
3. Delfraissy JF (under the direction of). Therapeutic management of human immunodeficiency virus-infected subjects (recommendations of the group of experts), Report to the Minister of Health, 2004 [www.sante.gouv.fr/htm/actu/delfraissy_2004/rapport.pdf].
4. Royal College of Obstetricians and Gynaecologists (RCOG). Management of HIV in pregnancy. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); April 2004 (Guideline; no. 39).
5. Mandelbrot L., Mayaux M.J., Bongain A., et al. Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group. Am J Obstet Gynecol 175 (1996) 661-667
6. Shapiro D.E., Sperling R.S., Mandelbrot L., Britto P., and Cunningham B.E. Risk factors for perinatal human immunodeficiency virus transmission in patients receiving zidovudine prophylaxis. Pediatric AIDS Clinical Trials Group protocol 076 Study Group. Obstet Gynecol 94 (1999) 897-908
7. Coll O., Fiore S., Floridia M., et al. Pregnancy and HIV infection: a European consensus on management. AIDS 16 Suppl 2 (2002) S1-S18
8. Royal College of Obstetricians and Gynaecologists. Amniocentesis and chorionic villus sampling. RCOG Guideline no. 8; 2005, 1-11.
9. Maiques V., Garcia-Tejedor A., Perales A., Cordoba J., and Esteban R.J. HIV detection in amniotic fluid samples: amniocentesis can be performed in HIV pregnant women?. Eur J Obstet Gynecol Reprod Biol 108 (2003) 137-141
10. Somigliana E., Bucceri A.M., Tibaldi C., et al. Italian Collaborative Study on HIV infection in pregnancy. Early invasive diagnostic techniques in pregnant women who are infected with the HIV: a multicenter case series. Am J Obstet Gynecol (2005) 437-442
11. Coll O., Suy A., Hernandez S., et al. Prenatal diagnosis in human immunodeficiency virus-infected women: a new screening program for chromosomal anomalies. Am J Obstet Gynecol 194 (2006) 192-198
12. Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Rockville (MD): U.S. Public Health Service; July 6, 2006.
13. Sperling R.S., Shapiro D.E., Coombs R.W., et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 335 (1996) 1621-1629
14. Mayaux M.J., Dussaix E., Isopet J., et al. Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. SEROGEST Cohort Group. J Infect Dis 175 (1997) 172-175
15. Cadman J. Rapid advances in preventing vertical transmission. GMHC Treat Issues 11 (1997) 25-31
16. Pappalardo B.L. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. Int J Epidemiol 32 (2003) 727-734
17. Tess B.H., Rodrigues L.C., Newell M.L., Dunn D.T., and Lago T.D. Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in Sao Paulo State, Brazil. Sao Paulo Collaborative Study for Vertical Transmission of HIV-1. AIDS 12 (1998) 513-520
18. Bucceri A.M., Somigliana E., and Vignali M. Early invasive diagnostic techniques during pregnancy in HIV-infected women. Acta Obstet Gynecol Scand 80 (2001) 82-83
19. Davies G., Wilson R.D., Desilets V., et al. Society of obstetricians and gynaecologists of Canada. Amniocentesis and women with hepatitis B, hepatitis C, or human immunodeficiency virus. J Obstet Gynaecol Can 25 (2003) 145-148
20. Wald N.J., Morris J.K., Ibison J., Wu T., and George L.M. Screening in early pregnancy for pre-eclampsia using down syndrome quadruple test markers. Prenat Diagn 26 (2006) 559-564
21. Yaron Y., Cherry M., Kramer R.L., et al. Second-trimester maternal serum marker screening: maternal serum alpha-protein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 181 (1999) 968-974
22. Spencer K., Cowans N.J., Avgidou K., and Nicolaides K.H. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death. Ultrasound Obstet Gynecol 28 (2006) 637-643
23. Suy A., Martinez E., Coll O., et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 20 (2006) 59-66